Irregularities found during FDA inspection of Intas Pharmaceuticals

Re:Irregularities found during FDA inspection of Intas Pharm... by jacksnipe on Wednesday June 28, 2023 @11:05AM (#36507516)

I wouldn’t be surprised. Concerta (osmotic time release) is so much more effective than normal generics (non-osmotic time release) that they shouldn’t even be considered the same drug.

[ Parent | on HN ]

Re:Irregularities found during FDA inspection of Intas Pharm... by bamfly on Wednesday June 28, 2023 @11:13AM (#36507656)

Yeah, our experience is something like:

    unmedicated << generic <<<<<<<<<<<<<<<<<<<<<<<<<<<<< name brand

in terms of perceived effect. They're sure as hell not close enough to be considered equivalent under any reasonable classification scheme (but I assume insurers really, really, really want the generic to count as equivalent and work to ensure it is so-regarded—and, anyway, availability's so spotty that we just have to take what we can get regardless).

[ Parent | on HN ]

Re:Irregularities found during FDA inspection of Intas Pharm... by jacksnipe on Thursday June 29, 2023 @05:36PM (#36527071)

As a patient this was also my experience.

[ Parent | on HN ]